Day One Biopharmaceuticals, Inc. (DAWN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
DAWN currently has 103M outstanding shares. with moderate dilution risk from 44.6M authorized shares representing 43.2% potential dilution. The company has diluted shareholders by 22.08% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 04, 2025 |
10-Q filing | 103.4M shares outstanding |
100M | 45M |
| Aug 05, 2025 |
10-Q filing | 103.1M shares outstanding |
100M | 45M |
| May 06, 2025 |
10-Q filing | 102.7M shares outstanding |
100M | 45M |
| Feb 25, 2025 |
10-K filing | 93.2M shares outstanding |
93M | 45M |
| Oct 30, 2024 |
10-Q filing | 96.9M shares outstanding |
97M | 45M |
| Aug 02, 2024 |
10-Q filing | 87.1M shares outstanding |
87M | 45M |
| May 06, 2024 |
10-Q filing | 86.7M shares outstanding |
87M | 45M |
| Feb 26, 2024 |
10-K filing | 79.8M shares outstanding |
80M | 45M |
| Nov 06, 2023 |
10-Q filing | 86.0M shares outstanding |
86M | 45M |
| Aug 07, 2023 |
10-Q filing | 87.0M shares outstanding |
87M | 45M |
| May 01, 2023 |
10-Q filing | 72.0M shares outstanding |
72M | 45M |
| Mar 06, 2023 |
10-K filing | 73.6M shares outstanding |
74M | 45M |
| Nov 07, 2022 |
10-Q filing | 71.0M shares outstanding |
71M | 45M |
| Aug 04, 2022 |
10-Q filing | 73.5M shares outstanding |
73M | 45M |
| Jun 01, 2022 |
S-3 filing: Day One Biopharmaceuticals, Inc. may offer up to $400 million aggregate dollar amount of shares of our common stock or preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities, in any combination. |
62M | 45M |
| May 12, 2022 |
10-Q filing | 61.9M shares outstanding |
62M | 21M |
| Mar 07, 2022 |
10-K filing | 62.0M shares outstanding |
62M | 21M |
| Nov 08, 2021 |
10-Q filing | 61.9M shares outstanding |
62M | 21M |
| Aug 10, 2021 |
10-Q filing | 61.9M shares outstanding |
62M | 21M |
| May 26, 2021 |
S-1/A filing: S-1/A filing for offering of common stock and an option to purchase additional shares, intending to use the net proceeds for clinical trials, development, and general corporate purposes. |
60M | 21M |
| May 24, 2021 |
S-1/A filing: This S-1/A filing discusses the number of shares of restricted common stock to be issued upon conversion of incentive shares, with an assumed fair value of $15.00 per common share. |
N/A | 0 |
| May 04, 2021 |
S-1 filing: S-1 filing for common stock offering. The company intends to use the net proceeds from this offering to advance the continued development of DAY101, fund further development or acquisitions of future preclinical and clinical programs towards IND filings and/or into clinical trials, and fund pre-commercialization activities for DAY101, working capital and other general corporate purposes. |
N/A | 0 |